Department of Reproductive Health, World Health Organization, Geneva, Switzerland.
World Health Organization Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, Örebro University, Örebro, Sweden.
Sex Transm Dis. 2019 Mar;46(3):179-184. doi: 10.1097/OLQ.0000000000000943.
Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is compromising the treatment of gonorrhea globally. Recent AMR data are extremely limited in Africa, and mainly totally lacking in Western Africa, including Côte d'Ivoire. This study (i) established a quality-assured gonococcal antimicrobial surveillance program, according to World Health Organization quality criteria, (ii) investigated the AMR to 8 therapeutic antimicrobials in gonococcal isolates from 2014 to 2017, and (iii) provided evidence for updating the National Sexually Transmitted Disease Syndromic Management Guidelines in Côte d'Ivoire.
During 2014 to 2017, gonococcal isolates were obtained from sexually active symptomatic or asymptomatic males and females in 14 sites in Côte d'Ivoire. It was a special focus on symptomatic males, and their sexual partners, due to the higher culture positivity rates in symptomatic males. Patient metadata were collected, including age, gender, sexual orientation, and symptoms. Minimum inhibitory concentrations of 8 antimicrobials were determined by Etest and interpreted using European Committee on Antimicrobial Susceptibility Testing breakpoints. β-lactamase production was detected using cefinase disks.
The level of resistance, examining 212 gonococcal isolates, was as follows: 84.9% to tetracycline, 68.9% to benzylpenicillin, 62.7% to ciprofloxacin, 6.1% to azithromycin, and 1.4% to gentamicin. All isolates were susceptible to ceftriaxone, cefixime and spectinomycin.
We provide the first gonococcal AMR data, quality assured according to World Health Organization standards, from Côte d'Ivoire since more than 20 years. The high ciprofloxacin resistance, which informed a revision of the national syndromic management guideline during study, and relatively high resistance to azithromycin demand an improved gonococcal antimicrobial surveillance program and increased awareness when prescribing treatment in Côte d'Ivoire.
淋病奈瑟菌的抗菌药物耐药性(AMR)正在全球范围内影响淋病的治疗。最近的 AMR 数据在非洲极为有限,在包括科特迪瓦在内的西非地区基本完全缺乏。本研究(i)根据世界卫生组织的质量标准,建立了一个经过质量保证的淋球菌抗菌药物监测方案;(ii)调查了 2014 年至 2017 年期间 8 种治疗性抗菌药物对淋病奈瑟菌分离株的耐药性;(iii)为更新科特迪瓦国家性传播疾病综合征管理指南提供了证据。
2014 年至 2017 年期间,从科特迪瓦 14 个地点的有症状或无症状的性活跃男性和女性中获得淋病奈瑟菌分离株。特别关注有症状的男性及其性伴侣,因为他们的培养阳性率更高。收集了患者的元数据,包括年龄、性别、性取向和症状。使用 Etest 测定 8 种抗菌药物的最低抑菌浓度,并根据欧洲抗菌药物敏感性测试委员会的折点解释结果。使用头孢菌素酶纸片检测β-内酰胺酶的产生。
对 212 株淋病奈瑟菌的耐药性检测结果如下:84.9%对四环素耐药,68.9%对青霉素耐药,62.7%对环丙沙星耐药,6.1%对阿奇霉素耐药,1.4%对庆大霉素耐药。所有分离株均对头孢曲松、头孢克肟和壮观霉素敏感。
我们提供了自 20 多年来科特迪瓦第一份按照世界卫生组织标准进行质量保证的淋球菌 AMR 数据。由于研究期间国家综合征管理指南的修订,发现了高比例的环丙沙星耐药性,以及相对较高的阿奇霉素耐药性,这需要在科特迪瓦改进淋球菌抗菌药物监测方案,并提高在开具治疗药物时的认识。